[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015022820A8 - trial to select a treatment regimen for an individual with depression, use of a compound comprising folate, composition and kit - Google Patents

trial to select a treatment regimen for an individual with depression, use of a compound comprising folate, composition and kit Download PDF

Info

Publication number
BR112015022820A8
BR112015022820A8 BR112015022820A BR112015022820A BR112015022820A8 BR 112015022820 A8 BR112015022820 A8 BR 112015022820A8 BR 112015022820 A BR112015022820 A BR 112015022820A BR 112015022820 A BR112015022820 A BR 112015022820A BR 112015022820 A8 BR112015022820 A8 BR 112015022820A8
Authority
BR
Brazil
Prior art keywords
depression
individual
folate
compound
treatment regimen
Prior art date
Application number
BR112015022820A
Other languages
Portuguese (pt)
Other versions
BR112015022820A2 (en
Inventor
Kronlage David
Papakostas George
O Koch Harold Jr
Fava Maurizio
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/796,362 external-priority patent/US9546401B2/en
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015022820A2 publication Critical patent/BR112015022820A2/en
Publication of BR112015022820A8 publication Critical patent/BR112015022820A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "ensaios e métodos para selecionar um regimene de tratamento para um indivíduo com depressão". a presente invenção refere-se a ensaios, métodos e composições para selecionar um regime de tratamento para um paciente tendo depressão ou em risco para depressão e/ou tratar pelo menos um sintoma de depressão no indivíduo, com base no reconhecimento que combinações específicas de polimorfismos de nucleotídeo simples (snps) estão associadas com uma resposta terapêutica para um composto compreendendo folato. fornecidos aqui são da mesma forma métodos para melhorar a eficácia de um fármaco antidepressivo administrado a um indivíduo com depressão ou em risco para depressão administrando-se uma terapia adjuntiva de um composto compreendendo folato ao indivíduo se o indivíduo transporta uma combinação específica de snps que é previsível de uma resposta terapêutica. além disso, fornecidas aqui são as composições do composto compreendendo folato.Patents and Methods for Selecting a Treatment Regimen for a Depressed Individual. The present invention relates to assays, methods and compositions for selecting a treatment regimen for a patient having depression or at risk for depression and / or treating at least one depression symptom in the individual, based on the recognition that specific combinations of polymorphisms. single nucleotide (snps) are associated with a therapeutic response to a folate-comprising compound. provided herein are likewise methods for improving the efficacy of an antidepressant drug administered to an individual with depression or at risk for depression by administering adjunctive therapy of a folate-comprising compound to the individual if the individual carries a specific combination of snps which is predictable outcome of a therapeutic response. further provided herein are compositions of the compound comprising folate.

BR112015022820A 2013-03-12 2014-03-11 trial to select a treatment regimen for an individual with depression, use of a compound comprising folate, composition and kit BR112015022820A8 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361777650P 2013-03-12 2013-03-12
US13/796,362 US9546401B2 (en) 2011-11-14 2013-03-12 Assays and methods for selecting a treatment regimen for a subject with depression
US201361914338P 2013-12-10 2013-12-10
PCT/US2014/023695 WO2014164882A1 (en) 2013-03-12 2014-03-11 Assays and methods for selecting a treatment regimen for a subject with depression

Publications (2)

Publication Number Publication Date
BR112015022820A2 BR112015022820A2 (en) 2017-07-18
BR112015022820A8 true BR112015022820A8 (en) 2019-11-26

Family

ID=51658998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022820A BR112015022820A8 (en) 2013-03-12 2014-03-11 trial to select a treatment regimen for an individual with depression, use of a compound comprising folate, composition and kit

Country Status (12)

Country Link
EP (1) EP2973135A4 (en)
JP (1) JP2016518816A (en)
KR (1) KR20150131147A (en)
CN (1) CN105518685A (en)
AU (1) AU2014248949A1 (en)
BR (1) BR112015022820A8 (en)
CA (1) CA2904418A1 (en)
IL (1) IL241156A0 (en)
MX (1) MX2015012520A (en)
RU (1) RU2015143177A (en)
TW (1) TW201437635A (en)
WO (1) WO2014164882A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177630A1 (en) * 2012-06-01 2013-12-05 Brc Operations Pty Limited Biomakers for treatment outcomes
EP3229812A4 (en) 2014-12-08 2018-10-03 Glycom A/S Synthetic composition for treating metabolic disorders
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
WO2016135707A1 (en) * 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
EP3368046B1 (en) 2015-10-28 2022-07-27 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
KR101911339B1 (en) * 2017-07-17 2018-10-25 고려대학교 산학협력단 Methylation rate of catecholamine-O-methyl transferase gene for providing information about diagnosis of major depressive disorder
EP3821982B1 (en) * 2018-07-12 2024-07-10 Korea Research Institute of Bioscience and Biotechnology Substrate for nucleic acid amplification, and method for manufacturing same
CN109234383A (en) * 2018-11-07 2019-01-18 上海康黎医学检验所有限公司 Kit relevant to resisting mental disease medicine, target gene and its preparation, SNP marker, SNP identification and application
CN109966498A (en) * 2019-03-25 2019-07-05 北京坤秋健康科技有限公司 A kind of medical composition and its use of depression
CN111500709A (en) * 2020-05-12 2020-08-07 珠海横琴润孚创新科技有限公司 Metabolic disease gene detection and clinical depth data analysis method
KR102570458B1 (en) * 2021-01-21 2023-08-24 전남대학교산학협력단 Asessment methods and diagnostic kit for depressive disorders in women using genetic biomarkers
JP7432190B2 (en) * 2021-03-01 2024-02-16 勝彦 山▲崎▼ Data acquisition methods and kits for identifying patients with antidepressant-resistant major depression
WO2023082401A1 (en) * 2021-11-11 2023-05-19 中国科学院深圳理工大学(筹) Genetic diagnostic kit and system for predicting response of patients suffering from depressive disorder to treatment
WO2023237306A1 (en) 2022-06-09 2023-12-14 Dsm Ip Assets B.V. Nutritional composition comprising gos and hmos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216737A1 (en) * 2005-03-10 2006-09-28 John Bodeau Methods for multiplex amplification
US20120115147A1 (en) * 2010-11-05 2012-05-10 Lombard Jay L Neuropsychiatric test reports
US20100304391A1 (en) * 2009-05-29 2010-12-02 Lombard Jay L Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
WO2011041611A1 (en) * 2009-09-30 2011-04-07 The Regents Of The University Of California Cofactors and methods for use for individuals
WO2012128799A2 (en) * 2010-12-03 2012-09-27 General Hospital Corporation, The Treating schizophrenia
IN2014DN04226A (en) * 2011-11-14 2015-05-22 Gen Hospital Corp

Also Published As

Publication number Publication date
RU2015143177A (en) 2017-04-18
BR112015022820A2 (en) 2017-07-18
CN105518685A (en) 2016-04-20
IL241156A0 (en) 2015-11-30
TW201437635A (en) 2014-10-01
AU2014248949A1 (en) 2015-09-10
MX2015012520A (en) 2016-01-12
EP2973135A1 (en) 2016-01-20
KR20150131147A (en) 2015-11-24
WO2014164882A1 (en) 2014-10-09
EP2973135A4 (en) 2016-11-16
JP2016518816A (en) 2016-06-30
CA2904418A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
BR112015022820A8 (en) trial to select a treatment regimen for an individual with depression, use of a compound comprising folate, composition and kit
CO2018012482A2 (en) Formulations of an lsd1 inhibitor
BR112020017090A8 (en) MICROBIOME-RELATED IMMUNOTHERAPIES
BR112018008358A2 (en) ? compositions and methods for fecal microbiota-related therapy?
BR112014015955A2 (en) subcutaneous therapeutic use of dpp-4 inhibitor
BR112016014481A2 (en) cancer treatment using combinations of erk and raf inhibitors
BR112015026006A8 (en) compound in combination with an imid® immunomodulatory drug, pharmaceutical composition comprising them, use of the same and kit
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
BR112014024672A8 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
BR112015027288A8 (en) use of an immunosuppressant dose, composition of synthetic tolerogenic nanocarriers and kit
BR112015009624A2 (en) bruton tyrosine kinase inhibitors
BR112015022514A2 (en) compositions comprising selenium and their use for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
BR112015016681A8 (en) use of nanoparticles comprising paclitaxel and an albumin, kit, drug, composition and unit dosage form for the treatment of pancreatic cancer
BR112015026297A2 (en) combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment
AR065033A1 (en) METHODS TO PREVENT AND TREAT NEURODEGENERATIVE DISORDERS
BR112013010021A2 (en) pharmaceutical combinations for the treatment of metabolic disorders.
BR112016027041A8 (en) pharmaceutical combinations for cancer treatment
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
AR067903A1 (en) METHOD TO TREAT STRESSED DEPRESSION
BR112012027197A2 (en) combination or pharmaceutical composition, its use, kit, and compounds for treating oncological and fibrotic diseases
BR112016026560A2 (en) METHOD FOR TREATMENT OF A COMPLICATION OF CHRONIC LIVER DISEASE, METHOD FOR TREATMENT PORTAL HYPERTENSION, METHOD FOR INHIBITING A CASCADE OF TNF-A AND A-FAS SIGNALING; PHARMACEUTICAL COMPOSITION, KIT, METHOD OF TREATMENT, METHOD FOR TREAT A DISEASE
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
BR112018006039A2 (en) adjuvant therapy with 25-hydroxyvitamin d and articles therefor
BR112014013924A8 (en) Methods To Treat Cardiovascular Disorders
BR112018002550A2 (en) inhibitor resistance mechanism

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements